SCHEMBL6401970

SCHEMBL6401970

O=P(O)(O)c1cccc(O)c1CCCCc1ccc(O)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 3/20 0.49
SGMS1 Q86VZ5 2/20 0.49
SGMS2 Q8NHU3 2/20 0.49
SLC28A3 Q9HAS3 1/20 0.46
IGF1R P08069 1/20 0.44
ALOX15 P16050 1/20 0.44
ESR1 P03372 3/20 0.41
ADRA2A P08913 2/20 0.41
ADORA3 P0DMS8 2/20 0.41
TACR2 P21452 2/20 0.41
SLC6A2 P23975 2/20 0.41
SLC6A4 P31645 2/20 0.41
SLC6A3 Q01959 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
SHBG P04278 1/20 0.41
TP53 P04637 1/20 0.41
CYP3A4 P08684 1/20 0.41
HSPD1 P10809 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6401901 0.97 SLC28A3 (0.50) ACHESGMS1SGMS2SLC28A3IGF1R
SCHEMBL6403831 0.91 ESR1 (0.45) ACHESGMS1SGMS2SLC28A3IGF1R
SCHEMBL6403912 0.85 MGLL (0.47) CHRM2CHRM1CHRM3MGLL
SCHEMBL6397457 0.82 MGLL (0.43) SLC28A3CHRM2CHRM1CHRM3MGLL
SCHEMBL6397728 0.82 SLC28A3 (0.63) ACHESGMS1SGMS2SLC28A3IGF1R
SCHEMBL6395084 0.79 SLC28A3 (0.68) ACHESGMS1SGMS2SLC28A3IGF1R
SCHEMBL6401967 0.78 ACHE (0.46) ACHESGMS1SGMS2SLC28A3IGF1R
SCHEMBL6396051 0.78 ACHE (0.46) ACHESGMS1SGMS2SLC28A3IGF1R
SCHEMBL6401949 0.77 ACHE (0.66) ACHESGMS1SGMS2SLC28A3ESR1
SCHEMBL6399784 0.77 ACHE (0.42) ACHESGMS1SGMS2SLC28A3IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans PEERCE BRIAN E (US) 2005-08-25 US disclosed
US-6787528-B2 THERAPY FOR KIDNEY DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-09-07 US disclosed
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-28 US disclosed
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation PEERCE BRIAN E (US) 2002-09-19 US disclosed
US-6355823-B1 MEMBRANE SUBSTRATE PHOSPHATED FOR DRUGS FOR GASTROINTESTINAL DISORDERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 ACHE 4868/4885SGMS1 3968/4885SGMS2 4314/4885
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation SLC10A2, SLC34A3, SLC34A1 ACHE 4865/4885SGMS1 4101/4885SGMS2 4281/4885
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 ACHE 4868/4885SGMS1 3968/4885SGMS2 4314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.